Association Between Polycystic Ovary Syndrome and Metabolic Syndrome

Author(s): Leandro Martin Velez, Alicia Beatriz Motta

Journal Name: Current Medicinal Chemistry

Volume 21 , Issue 35 , 2014

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer


Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorder affecting women in reproductive age. Although the etiology of PCOS remains unclear, it is believed to result from genetic, environmental and behavioral interactions. Women with PCOS have higher lifetime risk for cardiovascular disease (CVR) than healthy women at the same age and tend to display insulin resistance (IR). IR has traditionally been defined as a decreased ability of insulin to mediate the metabolic actions on glucose uptake, glucose production, and/or lipolysis. This results in a requirement for increased amounts of insulin to achieve a given metabolic action.

Metabolic syndrome (MS) includes hyperinsulinemia, dyslipidemia, increased CVR and hyperleptinemia and metabolic disorders such as hypertension, IR, gestational diabetes, type 2 diabetes mellitus, systemic inflammation and endothelial dysfunction. The prevalence of MS in women is around 50 %. In addition, it has been recently suggested that women with MS show increased circulating androgens. The present review discusses the main alterations and features of PCOS and MS and the most important treatments.

Keywords: cardiovascular disease, diabetes, glitazones, hyperandrogenism, insulin resistance, lipids, metabolic syndrome, metformin, obesity, polycystic ovary syndrome, simvastatin, statins.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 23 October, 2014
Page: [3999 - 4012]
Pages: 14
DOI: 10.2174/0929867321666140915141030
Price: $65

Article Metrics

PDF: 56